Artemotil Artecef.
The ethyl ether derivative of artemesinin, artemotil, has been developed by Artecef for the potential treatment of malaria. Adult and pediatric intramuscular formulations of the product were filed for approval in The Netherlands in January 1997 [236187]; registration for the two formulations followed in May 2000 [401672].
Yeates
Rodney A
RA
Rodney.Yeates@t-online.de
D000818:Animals; D000962:Antimalarials / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology*; D037621:Artemisinins; D002986:Clinical Trials as Topic; D006801:Humans; D016778:Malaria, Falciparum / Q000188:drug therapy; D012717:Sesquiterpenes / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology*; D013329:Structure-Activity Relationship
D000962:Antimalarials; D037621:Artemisinins; D012717:Sesquiterpenes; C055141:artemotil